Evidence map›Paper›PMID 25715048›Full record

ReviewHuman vaccines & immunotherapeutics2015

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae.

Miguel O'Ryan, Roberto Vidal, Felipe del Canto, Juan Carlos Salazar, David Montero

Open access · bronzeAbstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Frontiers in medicine · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Thiocarbamates fromBioMed research international · 2017
    Article
  10. Review
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Miguel O'Ryana Microbiology and Mycology Program; Institute of Biomedical Sciences; Universidad de Chile ; Santiago , Chile.
Roberto Vidal
Felipe del Canto
Juan Carlos Salazar
David Montero
Institute of Biomedical Science · GBUniversity of Chile · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Efforts to develop vaccines for prevention of acute diarrhea have been going on for more than 40 y with partial success. The myriad of pathogens, more than 20, that have been identified as a cause of acute diarrhea throughout the years pose a significant challenge for selecting and further developing the most relevant vaccine candidates. Based on pathogen distribution as identified in epidemiological studies performed mostly in low-resource countries, rotavirus, Cryptosporidium, Shigella, diarrheogenic E. coli and V. cholerae are predominant, and thus the main targets for vaccine development and implementation. Vaccination against norovirus is most relevant in middle/high-income countries and possibly in resource-deprived countries, pending a more precise characterization of disease impact. Only a few licensed vaccines are currently available, of which rotavirus vaccines have been the most outstanding in demonstrating a significant impact in a short time period. This is a comprehensive review, divided into 2 articles, of nearly 50 vaccine candidates against the most relevant viral and bacterial pathogens that cause acute gastroenteritis. In order to facilitate reading, sections for each pathogen are organized as follows: i) a discussion of the main epidemiological and pathogenic features; and ii) a discussion of vaccines based on their stage of development, moving from current licensed vaccines to vaccines in advanced stage of development (in phase IIb or III trials) to vaccines in early stages of clinical development (in phase I/II) or preclinical development in animal models. In this first article we discuss rotavirus, norovirus and Vibrio cholerae. In the following article we will discuss Shigella, Salmonella (non-typhoidal), diarrheogenic E. coli (enterotoxigenic and enterohemorragic), and Campylobacter jejuni.

Indexed as

Cholera VaccinesClinical Trials as TopicDiarrheaDrug ApprovalDrug DiscoveryDrug Evaluation, PreclinicalGastroenteritisHumansVibrio choleraeViral VaccinesVirusesCholera VaccinesViral VaccinesAce, accessory cholera enterotoxinacute diarrheaALA, aminolevulenic acidASC, antibody secreting cellcampylobacterCep, core encoded pilusCT-A cholera toxin A subunitCT-B cholera toxin B subunitCT, cholera toxinE. colienteric pathogensETECETEC, enterotoxigenic E. coligastroenteritisGEMS, global enteric multi-center studyHA/P, hemaglutinin proteaseHBGA, histo-blood group antibodiesIgA, immunoglobulin AIgG, immunoglobulin GIgM, immunoglobulin MIS, intussusceptionLB, lower boundaryLLR, Lanzhou Lamb Rotavirus vaccineLPS, lipopolysaccharideMPL, monophosphoril lipid AMSH, mannose-sensitive hemaglutinin pilusnorovirusRecA, recombinase Aremovable intestinal tie-adult rabbit diarrheaREST, rotavirus efficacy and safety trialRITARDrotavirusRR, relative risk, CI, confidence intervalSAES, serious adverse eventssalmonellashigellaSRSV, small round virus, ORF, open reading frameSTECSTEC, shigatoxin producing E. coliTCP, toxin co-regulated pilusVA1.3, vaccine attempt 1.3vaccinesV. choleraeVLPs, virus like particles, VRPs, virus replicon particlesVLP, virus like particleVP, viral proteinsWHO, World Health OrganizationZot, zonula occludens toxin

Identifiers

PMID25715048
PMCPMC4514277
OpenAlexW1880029546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.